Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
2.
Pancreatology ; 21(1): 69-73, 2021 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-33257225

RESUMO

BACKGROUND/OBJECTIVES: Acute pancreatitis management guidelines recommend early aggressive hydration to improve clinical outcomes. We aim to evaluate the influence of early fluid therapy (total intravenous fluids in the first 24 h [IVF/24hrs]) on clinical outcomes in patients with acute pancreatitis. METHODS: This was a retrospective chart review of all patients admitted for acute pancreatitis between July 2011 to December 2015. IVF/24hrs was categorized into 3 groups according to tertiles. Logistic regression was performed to evaluate predictors of persistent organ failure and in-hospital mortality. RESULTS: A total of 310 patients were included: Conservative (IVF/24hrs < 2.8L, n = 102), Moderate (IVF/24hrs 2.8-4.475L, n = 105) and Aggressive (IVF/24hrs ≥ 4.475, n = 103). Most patients (80.6%) were African Americans, 91.3% had mild acute pancreatitis (BISAP score ≤ 2). The Aggressive IVF group had higher incidence of persistent organ failure (16.5% vs 4.9% and 7.6%, p = 0.013), and longer length of hospital stay (9.2 ± 10.7 vs 6.5 ± 7.3 and 6.8 ± 5.7 days, P = 0.032). However, IVF/24hr did not correlate with length of hospital stay (PCC 0.08, p = 0.174). On multivariate analysis, only organ failure at admission was an independent predictor of persistent organ failure (OR 16.1, p < 0.001). Persistent organ failure and local complications were found to be the only independent predictors in-hospital mortality (OR 27.6, p < 0.001 and OR 16.95, p = 0.001 respectively). There was no difference in clinical outcomes in African Americans compared to other races. CONCLUSIONS: More aggressive early IVF therapy in a predominantly mild acute pancreatitis cohort, was not associated with improvement in persistent organ failure, length of hospital stay, or in-hospital mortality.


Assuntos
Hidratação , Pancreatite/terapia , Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Pancreatite/patologia , Estudos Retrospectivos
3.
Transplantation ; 103(6): e159-e163, 2019 06.
Artigo em Inglês | MEDLINE | ID: mdl-30801544

RESUMO

BACKGROUND: Intravenous contrast-enhanced imaging is invaluable in diagnosing pathology following liver transplantation. Given the potential risk of contrast nephropathy associated with iodinated computed tomography contrast, alternate contrast modalities need to be examined, especially in the setting of renal insufficiency. The purpose of this study was to examine the renal safety of MRI with gadolinium following liver transplantation. METHODS: The study involved a retrospective analysis of 549 cases of abdominal MRI with low-dose gadobenate dimeglumine in liver transplant recipients at a single center. For each case, serum creatinine values before and after the MRI were compared. In addition, cases were analyzed for the development of nephrogenic systemic fibrosis. RESULTS: Pre-MRI creatinine values ranged from 0.32 to 6.57 mg/dL (median, 1.28 g/dL), with 191 cases having values ≥1.5 mg/dL (median, 1.86 g/dL). A comparison of the pre- and post-MRI creatinine values showed no significant difference, including those patients with pre-MRI values ≥1.5 mg/dL (mean change of -0.04 [95% confidence interval, -0.07 to -0.01; P = 0.004]). No cases of nephrogenic systemic fibrosis were noted. CONCLUSIONS: Our findings suggest that, irrespective of baseline renal function, MRI with gadobenate dimeglumine is a nonnephrotoxic imaging modality in liver transplant recipients. Importantly, this intravenous contrast-enhanced imaging modality can be considered in those posttransplant patients who have a contraindication to computed tomography contrast due to renal insufficiency.


Assuntos
Injúria Renal Aguda/induzido quimicamente , Meios de Contraste/efeitos adversos , Transplante de Fígado/efeitos adversos , Imageamento por Ressonância Magnética/efeitos adversos , Meglumina/análogos & derivados , Dermopatia Fibrosante Nefrogênica/induzido quimicamente , Compostos Organometálicos/efeitos adversos , Complicações Pós-Operatórias/diagnóstico por imagem , Injúria Renal Aguda/diagnóstico , Injúria Renal Aguda/epidemiologia , Administração Intravenosa , Adulto , Idoso , Biomarcadores/sangue , Meios de Contraste/administração & dosagem , Creatinina/sangue , Feminino , Georgia/epidemiologia , Humanos , Incidência , Masculino , Meglumina/administração & dosagem , Meglumina/efeitos adversos , Pessoa de Meia-Idade , Dermopatia Fibrosante Nefrogênica/diagnóstico , Dermopatia Fibrosante Nefrogênica/epidemiologia , Compostos Organometálicos/administração & dosagem , Complicações Pós-Operatórias/epidemiologia , Insuficiência Renal/diagnóstico , Insuficiência Renal/epidemiologia , Estudos Retrospectivos , Medição de Risco , Fatores de Risco , Fatores de Tempo
4.
Ann Thorac Surg ; 103(2): e127-e129, 2017 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-28109370

RESUMO

We report a patient with significant dysphagia from hypercontractile "jackhammer" esophagus and a midesophageal pulsion diverticulum. This was treated with a thoracoscopic diverticulectomy and a long esophageal myotomy sparing the lower esophageal sphincter (LES). We describe the clinical diagnosis and surgical treatment of this uncommon esophageal motility disorder. To our knowledge, this is the first report in the literature of a midesophageal diverticulum caused by jackhammer esophagus. We propose that in the setting of normal LES function, successful treatment should include diverticulectomy with an LES-sparing myotomy.


Assuntos
Divertículo Esofágico/complicações , Divertículo Esofágico/cirurgia , Transtornos da Motilidade Esofágica/etiologia , Esôfago/cirurgia , Anastomose Cirúrgica , Divertículo Esofágico/diagnóstico por imagem , Transtornos da Motilidade Esofágica/cirurgia , Esofagoscopia/métodos , Esôfago/anormalidades , Feminino , Seguimentos , Humanos , Manometria/métodos , Pessoa de Meia-Idade , Doenças Raras , Recuperação de Função Fisiológica , Medição de Risco , Índice de Gravidade de Doença , Tomografia Computadorizada por Raios X/métodos , Resultado do Tratamento
5.
Liver Transpl ; 21(11): 1340-6, 2015 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-25786913

RESUMO

Renal dysfunction in cirrhosis carries a high morbidity and mortality. Given the potential risk of contrast-induced nephropathy associated with iodinated intravenous contrast used in computed tomography (CT), alternate contrast modalities for abdominal imaging in liver transplant candidates need to be examined. The purpose of this study was to examine the renal safety of magnetic resonance imaging (MRI) with gadolinium in patients awaiting liver transplantation. The study involved a retrospective analysis of 352 patients of abdominal MRI with low-dose gadobenate dimeglumine (MultiHance) (0.05 mmol/kg) in patients with cirrhosis and without renal replacement therapy at a single center during the period from 2007 to 2013. For each case, serum creatinine before and within a few days after the MRI were compared. In addition, the patients were analyzed for the development of nephrogenic systemic fibrosis (NSF), a reported complication of gadolinium in chronic kidney disease. The pre-MRI serum creatinine values ranged from 0.36 to 4.86 mg/dL, with 70 patients (20%) having values ≥ 1.5 mg/dL. A comparison of the pre- and post-MRI serum creatinine values did not demonstrate a clinically significant difference (mean change = 0.017 mg/dL; P = 0.38), including those patients with a pre-MRI serum creatinine ≥ 1.5 mg/dL. In addition, no cases of NSF were noted. In conclusion, our findings suggest that MRI with low-dose gadobenate dimeglumine (MultiHance) is a nonnephrotoxic imaging modality in liver transplant candidates, and its use can be cautiously expanded to liver transplant candidates with concomitant renal insufficiency.


Assuntos
Cirrose Hepática/complicações , Transplante de Fígado , Imageamento por Ressonância Magnética/métodos , Meglumina/análogos & derivados , Compostos Organometálicos/administração & dosagem , Insuficiência Renal/diagnóstico , Conduta Expectante/métodos , Meios de Contraste/administração & dosagem , Relação Dose-Resposta a Droga , Feminino , Seguimentos , Gadolínio , Humanos , Infusões Intravenosas , Cirrose Hepática/diagnóstico , Cirrose Hepática/cirurgia , Masculino , Meglumina/administração & dosagem , Pessoa de Meia-Idade , Insuficiência Renal/complicações , Reprodutibilidade dos Testes , Estudos Retrospectivos
6.
Transplant Rev (Orlando) ; 24(4): 190-206, 2010 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-20688502

RESUMO

The critical care management of patients before liver transplantation is aimed at optimizing hepatic and extrahepatic organ function before the transplant operation, with a goal to favorably influence perioperative and postoperative graft and patient outcomes. Critical illness in liver disease can present in the context of acute liver failure or acute on chronic liver failure. The differing pathophysiologic processes underlying these 2 types of liver failure necessitate specific approaches to their intensive care management. In their extreme presentations, both types of liver failure present as multiorgan system failure; and therefore, the critical care management of these entities requires a systematic multiorgan system approach to address hepatic and extrahepatic organ dysfunction. This review provides a multiorgan system-based description of critical care management of acute liver failure and acute on chronic liver failure before liver transplantation.


Assuntos
Transplante de Fígado/métodos , Cuidados Pré-Operatórios/normas , Acetaminofen/toxicidade , Acetilcisteína/toxicidade , Edema Encefálico/complicações , Overdose de Drogas/complicações , Doença Hepática Terminal/cirurgia , Doença Hepática Terminal/terapia , Síndrome Hepatopulmonar/cirurgia , Síndrome Hepatopulmonar/terapia , Homeostase , Humanos , Falência Hepática Aguda/induzido quimicamente , Falência Hepática Aguda/etiologia , Falência Hepática Aguda/cirurgia , Falência Hepática Aguda/terapia , Período Pós-Operatório , Cuidados Pré-Operatórios/métodos , Resultado do Tratamento
7.
J Gastroenterol ; 42(3): 250-2, 2007 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-17380284

RESUMO

Wells' syndrome, also termed eosinophilic cellulitis, is a dermatologic condition of unknown etiology that occurs as recurrent patches or plaques mimicking infectious cellulitis. Histopathology reveals an eosinophilic infiltrate and characteristic flame figures. Previous reports have associated this syndrome with parasitic infections, arthropod bites, pharmacologic agents, surgery, and hematologic disorders. We present a case report of a patient with Wells' syndrome associated with newly diagnosed ulcerative colitis. The dermatosis erupted concurrently with flares of ulcerative colitis. Furthermore, treatment of the ulcerative colitis led to resolution of the skin lesions. To our knowledge this describes the first association between inflammatory bowel disease and Wells' syndrome and argues for a distinct relationship between the two.


Assuntos
Celulite (Flegmão)/epidemiologia , Colite Ulcerativa/epidemiologia , Eosinofilia/epidemiologia , Adulto , Colonoscopia , Comorbidade , Feminino , Humanos , Síndrome
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...